Novel Angioplasty Using Coronary Accessor (NAUSICA)

February 6, 2019 updated by: Shigeru Saito, NAUSICA Investigators

Novel Angioplasty USIng Coronary Accessor

To investigate the advantage of using a 4Fr guiding catheter over a 6 Fr, frequencies of radial artery occlusion after transradial coronary intervention (TRI) will be evaluated. Radial artery occlusion rate in 4 Fr TRI group is expected to be not more than that in 6Fr groups.

Study Overview

Status

Completed

Detailed Description

Prerequisites for TRI were a sufficiently pulsating radial artery and presence of an ulnar pulse with a sufficient palmar arch, as evidenced by the absence of digital ischemia according to the Allen's test. Exclusion criteria for the current study included planned use of a cutting balloon, rotational atherectomy, directional coronary atherectomy, and intravascular ultrasound, which were not compatible with 4-Fr catheter.

Patency of the radial artery after TRI will be evaluated by pulsation of the radial artery, and frequencies of which will be compared between those receiving 4Fr vs 6 Fr coronary interventions.

Study Type

Interventional

Enrollment (Actual)

160

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • AP
      • Hyderabad, AP, India
        • Global Hospital
      • Secunderabad, AP, India, 500003
        • Krishna Institute of Medical Sciences
      • Aomori, Japan, 030-8553
        • Aomori Prefectural Central Hospital
      • Fukuoka, Japan, 813-0036
        • Fukuoka Heart Clinic
      • Kyoto, Japan, 601-8453
        • Kyoto Kujo Hospital
    • Aichi
      • Seto, Aichi, Japan, 489-8652
        • Tosei General Hospital
    • Chiba
      • Narashino, Chiba, Japan, 275-0006
        • Chibaken Saiseikai Narashino Hospital
    • Fukuoka
      • Kurume, Fukuoka, Japan, 830-8577
        • Shin-Koga Hospital
    • Hokkaido
      • Sapporo, Hokkaido, Japan, 065-0033
        • Sapporo Higashi Tokushukai Hospital
      • Sapporo, Hokkaido, Japan, 007-8505
        • Kin-ikyo Central Hospital
    • Hyogo
      • Kobe, Hyogo, Japan, 654-0026
        • Sakurakai Takahashi Hospital
      • Nishinomiya, Hyogo, Japan, 665-8501
        • Hyogo College of Medicine
    • Kanagawa
      • Atsugi, Kanagawa, Japan, 243-8551
        • Shonan Atsugi Hospital
      • Isehara, Kanagawa, Japan, 259-1193
        • Tokai University
      • Kamakura, Kanagawa, Japan, 247-8533
        • Shonan Kamakura General Hospital
      • Yokohama, Kanagawa, Japan, 232-0024
        • Yokohama City University Medical Center
    • Kumamoto
      • Yatsushiro, Kumamoto, Japan, 866-8533
        • Kumamoto Rosai Hospital
    • Tochigi
      • Shimotsuke, Tochigi, Japan, 329-0498
        • Jichi Medical University
    • Pai-Tou
      • Taipei, Pai-Tou, Taiwan, 112
        • Cheng Hsin General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Prerequisites for transradial intervention were a sufficiently pulsating radial artery and presence of an ulnar pulse with a sufficient palmar arch, as evidenced by the absence of digital ischemia according to the Allen's test.

Exclusion Criteria:

  • Exclusion criteria included planned use of a cutting balloon, rotational atherectomy, directional coronary atherectomy, and intravascular ultrasound, which were not compatible with 4-Fr catheter.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Sham Comparator: 6-Fr TRI (transradial coronary intervention)
TRI will be performed using a 6-Fr guiding catheter.
PCI will be performed via the radial artery.
Active Comparator: 4-Fr TRI
TRI will be performed using a 4-Fr guiding catheter.
PCI will be performed via the radial artery.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Patients With Radial Artery Occlusion
Time Frame: within 2 days after TRI
The primary endpoint was radial artery occlusion the day after TRI, defined as the absence of a radial pulse confirmed by a reverse Allen's test.
within 2 days after TRI

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Patients With Successful PCI
Time Frame: within 2 days after TRI
Procedural success was defined as a postprocedural residual stenosis of less than 20%, and a thrombolysis in myocardial infarction (TIMI) grade 3 angiographic flow without MACE during in-hospital follow-up.
within 2 days after TRI
Number of Patients With Measure Adverse Cardiac Event (MACE)
Time Frame: within 2 days after TRI
Defined as a composite of cardiac death, myocardial infarction, and target lesion revascularization
within 2 days after TRI
Number of Patients With Access-site Complications
Time Frame: within 2 days after TRI
Access-site-related complications were defined as bleeding, pseudoaneurysm, arteriovenous fistula, and occlusion of the radial artery, which were considered to be major if they were associated with a vascular repair or a blood transfusion.
within 2 days after TRI
Fluoroscopy Time Used for the Procedure
Time Frame: At the end of TRI
Fluoroscopy time used for the procedure (minutes).
At the end of TRI
Contrast Dye Volume Used for the Procedure
Time Frame: At the end of TRI
Contrast dye volume used for the procedure (mL).
At the end of TRI
Time Used for the Procedure
Time Frame: At the end of TRI
Time used for the procedure (minutes).
At the end of TRI
Time Used for Hemostasis
Time Frame: within 2 days afterTRI
Time Used for Hemostasis (minutes).
within 2 days afterTRI

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Shigeru Saito, MD, Vice Preseident, Shonan Kamakura General Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2009

Primary Completion (Actual)

December 31, 2010

Study Completion (Actual)

December 31, 2010

Study Registration Dates

First Submitted

December 29, 2008

First Submitted That Met QC Criteria

December 30, 2008

First Posted (Estimate)

December 31, 2008

Study Record Updates

Last Update Posted (Actual)

May 6, 2019

Last Update Submitted That Met QC Criteria

February 6, 2019

Last Verified

February 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • 2008-28

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Patency of the Radial Artery

Clinical Trials on PCI (percutaneous coronary intervention)

Subscribe